Mechanism of Action
MC4R-Specific Satiety Restoration
Setmelanotide activates MC4R in the paraventricular nucleus (PVN) and other hypothalamic nuclei, mimicking the downstream effect of alpha-msh/" class="wiki-internal-link">alpha-MSH derived from POMC. In conditions with POMC deficiency (no alpha-MSH produced), PCSK1 deficiency (POMC not cleaved to alpha-MSH), or LEPR deficiency (leptin/" class="wiki-internal-link">leptin cannot upregulate POMC neurons), MC4R signaling is absent. Setmelanotide directly activates MC4R via Gs/cAMP, restoring satiety signaling, reducing food intake, and increasing energy expenditure.
Selectivity vs Melanotan/Bremelanotide
Earlier melanocortin agonists (Melanotan II, bremelanotide/PT-141) activate MC1R (pigmentation), MC3R (energy homeostasis, immune), and MC4R (satiety, sexual function). Setmelanotide's cyclic lactam structure confers >40-fold selectivity for MC4R over MC1R and MC3R, reducing skin tanning and sexual side effects. This selectivity makes it suitable for chronic daily dosing for weight management without the cosmetic (tanning) and sexual effects of earlier non-selective analogues.
Hypothalamic Circuit Restoration
MC4R activation in the PVN drives downstream sympathetic nervous system activation and metabolic rate increase (thermogenesis), while reducing orexigenic NPY/AgRP signaling. In genetic obesity from melanocortin pathway defects, restoring this signaling dramatically reduces hyperphagia (the patients' primary symptom) often within days of starting treatment. The genetic defect defines which patients respond: pathway-deficient patients respond robustly; common polygenic obesity does not respond as well.
Research Summary
POMC/PCSK1/LEPR Deficiency (Approved)
Standard of CarePivotal trial (n=21 genetic obesity patients) showed setmelanotide produced mean body weight loss of 25.6% (POMC/PCSK1) and 12.5% (LEPR deficiency) over 52 weeks. All 5 patients with POMC deficiency achieved >10% weight loss vs none on placebo. Hunger scores improved dramatically. These are among the largest weight losses seen in any pharmacotherapy trial, reflecting the profound role of MC4R signaling in these specific genotypes.
Bardet-Biedl and Alstrom Syndromes
Clinical / ApprovedBBS and Alstrom syndrome involve ciliopathy-related hypothalamic signaling defects that impair MC4R pathway function through LEPR resistance and ciliary signaling abnormalities. RHYTHM Phase III trials in BBS (n=44) showed 9% weight loss over 52 weeks versus -0.1% placebo, with clinically meaningful hunger reduction. Imcivree was approved for BBS and Alstrom syndrome in 2022, expanding the rare disease indication significantly.
Broader Hypothalamic Obesity
ResearchResearch is ongoing for setmelanotide in hypothalamic obesity due to craniopharyngioma, cranial irradiation, and other POMC/MC4R pathway disruptions. Patients with acquired hypothalamic damage often have profound obesity refractory to lifestyle and standard pharmacotherapy. Early open-label data suggests some patients with hypothalamic obesity beyond the approved genetic causes respond to setmelanotide, prompting expanded clinical investigation.
Calculate your Setmelanotide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Genetic obesity (approved) | Start 2 mg SC daily; increase to 3 mg if tolerated at 2 weeks | Once daily SC | SC (abdomen, thigh, or upper arm) |
| Pediatric dosing | 0.5 mg SC daily; titrate by 0.5 mg weekly to max 3 mg | Once daily SC | SC injection |
| MC4R agonism research | 1-100 nM in vitro | Single concentration-response | Cell culture / receptor preparation |
Genetic testing required before use, FDA-approved for POMC, PCSK1, or LEPR mutations, BBS, and Alstrom syndrome only. Monitor for injection site reactions and depressive symptoms.
Interactions
Safety Profile
Setmelanotide is generally well-tolerated in approved populations. Injection site reactions (pain, erythema) are the most common adverse event. Skin hyperpigmentation (due to low-level MC1R activation despite selectivity) occurs in most patients, a cosmetic rather than medical concern. Nausea, vomiting, and diarrhea occur at initiation. Sexual side effects (spontaneous penile erections in males, sexual adverse events) are reported, reflecting residual MC4R activity on reproductive circuits. Depression and suicidal ideation require monitoring. Male sexual side effects can be managed with dose reduction.
References
- [1]Clément K, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nature Medicine. 2018.
- [2]Haws R, et al. Setmelanotide for the treatment of Bardet-Biedl syndrome: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2022.
- [3]Kühnen P, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016.